NCT04828603

Brief Summary

The purpose of this study is to strengthen our ability to accurately diagnose allergies and understand cellular, humoral, genetic components and physiological changes in allergic disease

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,500

participants targeted

Target at P75+ for all trials

Timeline
32mo left

Started Oct 2007

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
Oct 2007Dec 2028

Study Start

First participant enrolled

October 1, 2007

Completed
13.5 years until next milestone

First Submitted

Initial submission to the registry

March 30, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 2, 2021

Completed
7.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Last Updated

March 17, 2026

Status Verified

March 1, 2026

Enrollment Period

21.2 years

First QC Date

March 30, 2021

Last Update Submit

March 16, 2026

Conditions

Allergy

Outcome Measures

Primary Outcomes (1)

  • Skin testing to evaluate food allergen responses

    Standardized skin testing performed to detect sensitivity to allergens of interest

    1 year

Eligibility Criteria

Age1 Week - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients ages 1 week through 90 years who have or are suspected of having allergic sensitivities will be invited to participate

You may qualify if:

  • Any individual with possible allergy

You may not qualify if:

  • Patients with special risks attendant to venipuncture will be excluded

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sean N. Parker Center for Allergy and Asthma Research, Stanford University

Palo Alto, California, 94304, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples; additional samples could include sputum, urine sample, stool sample, oral and nasal samples, skin samples, gastrointestinal samples, and surgical tissues

MeSH Terms

Conditions

Hypersensitivity

Condition Hierarchy (Ancestors)

Immune System Diseases

Study Officials

  • R. Sharon Chinthrajah, MD

    Stanford University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

SNP Center Inquiry

CONTACT

(650) 521-7237snpcenterallergy_inquiry@stanford.edu

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor & Director, Clinical Translational Research Unit

Study Record Dates

First Submitted

March 30, 2021

First Posted

April 2, 2021

Study Start

October 1, 2007

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2028

Last Updated

March 17, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations

US(1)